Effect of Secretome Mesenchymal Stem Cells On Expression Interleukin 10 And Interleukin 17 in Mice Lupus Model

Abstract

Background: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune inflammatory disease with extensive clinical features. The role of Interleukin 10 (IL-10) is to promote autoantibody production and autoreactive B cell proliferation. Interleukin 17 (IL-17) associated with pathogenesis of SLE and positively correlated with disease activity. Intraperitoneal pristane can induce lupus in mice. Mesenchymal stem cells secretome work in paracrine effects asantiinflammatory and immunomodulation agent by suppressing autoreactive T and B cell, which play an important role in pathogenesis of SLE. The aim of this study is to evaluate effect of mesenchymal stem cells secretome on the expression of IL-10 and IL-17 in murine lupus models induced by pristane. Methods: A randomized experimental study, post-test only control group design, samples using 21 female Mus Musculus mice strain Balb/C, divided into 3 groups: control group with intraperitoneal injection of 0.5 mL of 0.9% NaCl, treatment group with intraperitoneal injection of 0.5 mL pristane, therapy group with intraperitoneal injection of 0.5 mL pristane and 0.45 mL of secretome. Statistical analysis using ANOVA test. A p-value < 0.05 was considered statistically significant. Results: The results showed significant relationship between control and pristane groups both at the levels of IL-17 (control 6.9±1.95,pristane 9.9±2.27, pristane+secretome 6.1±1.95 p=0.016), and there are significant differences in the expression of IL-10 in the control group vs pristane group (-4,42±1,43 per 100 lymphocyte; p=0,006), pristane group vs pristane+secretome group (4,00±1,43 per 100 lymphocyte; p=0,012). Conclusion: Mesenchymal stem cells secretome decreased the expression of IL-10 and IL-17 levels in murine lupus models induced by pristane.

MSC-EVs: A Promising Modulator for Immune Response in Systemic Lupus Erythematosus

“…Previous studies have also shown that MSCs alleviate lupus-like diseases by reducing the number of CD19 + B cells [39]. The secretions of MSCs reduce serum IL-10 levels in lupus mice [40]. This study demonstrated that hUCMSCs inhibited B cells; hUCMSC-EVs had on effects on B cells, and hUCMSCs or hUCMSC-EVs had no signi cant regulatory effects on IL-10.…”

The Effect of Mesenchymal Secretome Stem Cell Therapy toward Caspase-3 Expression in Pregnant Mice with Pristan-Induced Lupus Model

“…This suppressive effect was caused by improved function and activity of Treg cells and decreased Th17 cell levels (Figueora et al, 2014). With the decrease in IL-17 levels produced by Th17 cells, Treg activity, in regulating the appearance of antibodies to selfantigens would run better, so that theclinical improvement of LES occurred (Nurudhin et al, 2017).…”

Human umbilical cord mesenchymal stem cells derived extracellular vesicles regulate acquired immune response of lupus mouse in vitro

“…Previous studies have also shown that MSCs alleviate lupus-like diseases by reducing the number of CD19 + B cells 50 . The secretions of MSCs reduce serum IL-10 levels in lupus mice 51 . This study demonstrated that hUCMSCs inhibited B cells; hUCMSC-EVs had no effects on B cells, and hUCMSCs or hUCMSC-EVs had no significant regulatory effects on IL-10.…”